الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 139 |  |  |
| | | from | 139 | | |
Abstract
Androgenetic alopecia (AGA), characterized by a progressive miniaturization of terminal scalp hair with a pattern distribution, is the most common cause of hair loss in adults.
Topical finasteride is being investigated as a new treatment for AGA with fewer side effects than oral finasteride. A daily application of a 0.25% solution of finasteride (doses of 100 and 200 μL) leads to the inhibition of scalp DHT and may minimize the unwanted sexual side effects that are linked to systemic DHT reduction.
Topical Spironolactone is the most commonly used off-label anti-androgen for the treatment of FAGA. In the treatment of AGA, it acts by decreasing the production and competitively blocking the androgen receptor in the target tissue.
The aim of this study was to evaluate the role and compare the effect of topical finasteride and topical spironolactone in the treatment of androgenic alopecia (AGA).
There was statistically significant difference between focal atricha baseline and after 6 months in male patients.
There was no statistically significant difference in Ebling scale for females’ baseline and after 6 months between females using Finasteride and Spironolactone groups.
There was highly statistically significant difference between focal atricha baseline and after 6 months in female patients. There was statistically significant difference between Perpilar sign baseline and after 6 months in female patients.
There was no statistically significant difference between male and female in percent of increased hair count after treatment.